They are not the household names, but the medications they are researching and developing could be the lifeline patients are waiting for. Today we explore how drug price controls—now making their way through Congress—could have unintended consequences for the small biotechs that are the engine of the drug development ecosystem. And even worse, for the patients who need them most.
Ahmed Mousa, Pieris Pharmaceuticals
Daphne Zohar, PureTech Health
Peter Kolchinsky, RA Capital
Michele Oshman, BIO
Clare Thorpe, Library Services (AU)